Compare ALTO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTO | ASMB |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.2M | 442.9M |
| IPO Year | 2005 | 2010 |
| Metric | ALTO | ASMB |
|---|---|---|
| Price | $5.71 | $26.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 2.3M | 178.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | 91.78 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $917,927,000.00 | N/A |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $0.43 | $638.39 |
| P/E Ratio | $108.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $15.12 |
| 52 Week High | $6.00 | $39.71 |
| Indicator | ALTO | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 64.51 | 42.79 |
| Support Level | $4.27 | $26.40 |
| Resistance Level | $6.00 | $27.14 |
| Average True Range (ATR) | 0.33 | 1.68 |
| MACD | 0.08 | -0.18 |
| Stochastic Oscillator | 83.56 | 15.37 |
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.